About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Alzheimer's Disease Clinical Trials in Phoenix | 242 Studies

Clinical Trials Alzheimer's DiseasePhoenix

Alzheimer's Disease Clinical Trials in Phoenix

Find 242 clinical trials for alzheimer's disease near Phoenix, Arizona. Connect with research centers in your area.

All Alzheimer's Disease trials nationwide All trials in Phoenix

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 61-80 of 242 trials

CompletedSGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.NCT00093951·Phoenix, Arizona and 58 others

Alzheimer's Disease Trials in Other Cities

New York Los Angeles Chicago Houston Philadelphia San Antonio

Data from ClinicalTrials.govTerms

CompletedObservational Study on Costs and Caregiver Burden in Alzheimer's DiseaseObjective of study is to assess the costs of care, objective and subjective caregiver burden and quality of life in relation to disease severity measured by cognitive function…NCT00698165·Northport, Alabama and 81 others

TerminatedA Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseThe purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at…NCT03131453·Phoenix, Arizona and 193 others

CompletedA Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in…NCT00004845·Phoenix, Arizona and 39 others

TerminatedPhase 2 Study of BIIB092 in Participants With Early Alzheimer's DiseaseThe primary objective of the placebo-controlled period is to evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to…NCT03352557·Birmingham, Alabama and 100 others

CompletedSafety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's DiseaseThe purpose of this study is to determine in an 8-week treatment study if MEM 3454 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.NCT00454870·Phoenix, Arizona and 6 others

CompletedSafety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect…NCT00056524·Phoenix, Arizona and 38 others

TerminatedRandomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's DiseaseA multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's…NCT00021723·Peoria, Arizona and 10 others

TerminatedA Study of JNJ-63733657 in Participants With Early Alzheimer's DiseaseThe primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale…NCT04619420·Birmingham, Alabama and 121 others

CompletedA Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseThe purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).NCT03518073·Phoenix, Arizona and 59 others

Active not recruitingA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks.NCT05026866·Birmingham, Alabama and 215 others

CompletedSafety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on DonepezilThe purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.NCT00829374·Phoenix, Arizona and 100 others

CompletedELND005 in Patients With Mild to Moderate Alzheimer's DiseaseThe purpose of this study is to evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease (AD).NCT00568776·Phoenix, Arizona and 61 others

CompletedA Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's DiseaseThe purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer's disease over a treatment period of 12-weeks and…NCT00810147·Birmingham, Alabama and 40 others

RecruitingStudy to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseaseThis is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.NCT06808984·Homewood, Alabama and 76 others

TerminatedAn Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's DementiaThe purpose of this study is to evaluate whether treatment with atabecestat slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure…NCT02569398·Birmingham, Alabama and 127 others

CompletedA Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate ADThe purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's…NCT05686044·Gilbert, Arizona and 53 others

Enrolling by invitationThe Diabetes Prevention Program Outcomes Study AD/ADRD ProjectThe DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2…NCT05704309·Phoenix, Arizona and 26 others

RecruitingStudy of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's DiseaseThis study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis…NCT06847321·Phoenix, Arizona and 38 others

CompletedSimufilam 100 mg for Mild-to-Moderate Alzheimer's DiseaseA 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks.NCT04994483·Chandler, Arizona and 87 others

PreviousPage 4 of 13Next

Other Conditions in Phoenix

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia